^
Association details:
| Biomarker: | KIM1 elevation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
PLASMA KIM-1 IS ASSOCIATED WITH CLINICAL OUTCOMES AFTER RESECTION FOR LOCALIZED RENAL CELL CARCINOMA: A TRIAL OF THE ECOG-ACRIN RESEARCH GROUP (E2805)
Published date:
09/30/2019
Excerpt:
Elevated plasma KIM-1 is associated with worse DFS and OS in patients with resected RCC, and therefore has potential as an adjuvant biomarker.
DOI:
10.1093/annonc/mdz239
Trial ID:
